Category: Biomedical Advanced Research and Development Authority
Cue Health raises $100 million to speed development of rapid, portable COVID-19 diagnostics
San Diego-based startup Cue Health has closed a $100 million Series C funding round, including participation from Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital and others. The funding will be used to help Cue finish up development, validate and scale production of its Cue…
Read More
Emergent BioSolutions gets $14.5M in federal funding to expedite COVID-19 plasma therapy development
Last week, we spoke to the Head of Emergent BioSolutions’ Therapeutics Business Unit Dr. Laura Saward about her company’s work developing plasma-based potential treatments for COVID-19. Now, the company announced that it has received $14.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), which is part…
Read More
Cue Health awarded $13 million government contract to develop portable, point-of-care COVID-19 test
Biotech startup Cue Health has secured a $13 million contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test that can detect the presence of the SARS-CoV-2 novel…
Read More
Johnson & Johnson partners with BARDA to fund $1 billion in COVID-19 vaccine research
Pharmaceutical giant Johnson & Johnson is partnering with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to fund over $1 billion in COVID-19 vaccine and antiviral treatment research and development, the company said on Monday. The partnership is an expansion of an…
Read More